Some have relabeled it as Pentadecapeptide Aringate or PDA (modifying the acetate to an arginate) and are prescribing it for subcutaneous administration that way, when the confusion about its position has brought about a vibrant oral capsule marketplace for BPC in what seems to be a grey area of